Plus Therapeutics, Inc. announced that it has entered into an agreement with RadioMedix, Inc. for the commercial production of the Company’s radiopharmaceuticals. Under the agreement, RadioMedix will produce cGMP drug product meeting all applicable requirements of the U.S. Food and Drug Administration (FDA) and similar global regulatory entities. This strategic partnership further secures the commercial supply chain for 186RNL and extends to future products under the RNL platform. RNL is being developed to treat recurrent GBM, leptomeningeal metastases, and pediatric brain cancer. It has been designed to safely, effectively and conveniently deliver high doses of radiation to rare and central nervous system tumors. Plus Therapeutics is currently enrolling patients with recurrent GBM in the U.S.NIH-supported multi-center ReSPECT™-GBM Phase 1 dose-finding clinical trial.